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Background: New therapies are urgently needed for patients with small cell lung cancer (SCLC). Chemotherapy
and targeted therapies, including the Bcl-2 inhibitor ABT-737, may induce tumor cell autophagy. Autophagy can
promote survival of cancer cells under stress and comprise a pathway of escape from cytotoxic therapies.
Methods: We explored the combination of ABT-737 and chloroquine, an inhibitor of autophagy, in preclinical
models of SCLC. These included cell culture analyses of viability and of autophagic and apoptotic pathway
induction, as well as in vivo analyses of efficacy in multiple xenograft models.
Results: Combination treatment of SCLC lines with ABT-737 and chloroquine decreased viability and increased
caspase-3 activation over treatment with either single agent. ABT-737 induced several hallmarks of autophagy.
However, knockdown of beclin-1, a key regulator of entry into autophagy, diminished the efficacy of ABT-737,
suggesting either that the effects of chloroquine were nonspecific or that induction but not completion of
autophagy is necessary for the combined effect of ABT-737 and chloroquine. ABT-737 and chloroquine in SCLC cell
lines downregulated Mcl-1 and upregulated NOXA, both of which may promote apoptosis. Treatment of tumor-
bearing mice demonstrated that chloroquine could enhance ABT-737-mediated tumor growth inhibition against
NCI-H209 xenografts, but did not alter ABT-737 response in three primary patient-derived xenograft models.
Conclusion: These data suggest that although ABT-737 can induce autophagy in SCLC, autophagic inhibition by
choroquine does not markedly alter in vivo response to ABT-737 in relevant preclinical models, arguing against this
as a treatment strategy for SCLC.
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Autophagy is an evolutionarily conserved, reversible
process in which the cell degrades its own cytoplasmic
components utilizing lysosomal pathways. Typically, au-
tophagy is activated under conditions of cell stress, in-
cluding nutrient deprivation, environmental stressors,
accumulation of misfolded proteins, and growth factor
signal interruption. Cytoplasmic components are seques-
tered into double-membraned vesicles, or autophagosomes,
which then fuse with lysosomes and the contained material* Correspondence: rudin@jhmi.edu
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reproduction in any medium, provided the oris degraded to amino acids, nucleotides, sugars, and fatty
acids that are released into the cytoplasm for biosynthesis
and metabolism [1,2].
Recent evidence suggests that autophagy is frequently ac-
tivated in tumor cells treated with chemotherapy and radi-
ation [3-7]. While persistent activation of autophagy may
lead to tumor cell death, accumulating evidence suggests
that it can serve as a protective pathway for cells to escape
apoptotic cell death, allowing survival through periods of
stress, growth factor withdrawal, or nutrient deprivation
[8,9]. Several studies have shown that autophagy delayed
apoptotic death in cancer cells undergoing chemotherapeu-
tic treatment. Treatment of these cells with inhibitors of au-
tophagy, such as chloroquine, or knockdown of essentiald. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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hanced therapy-induced apoptosis [10-14]. Chloroquine
acts as a lysosomal pH inhibitor, therefore preventing the
fusion of autophagosomes with lysosomes and inhibiting
late stages of autophagy [15,16]. These findings have led to
the initiation of multiple clinical trials combining autophagy
inhibitors and chemotherapeutic agents for diverse cancer
types [17].
Small cell lung cancer (SCLC) comprises approximately
15% of all lung cancers and is a remarkably aggressive dis-
ease [18]. SCLC is characterized by rapid proliferation and
early dissemination to metastatic sites. While standard of
care platinum-based chemotherapy induces responses in
up to 80% of newly diagnosed SCLC cases, these responses
are short-lived: the median survival in patients with ad-
vanced SCLC is approximately 9 months from the time of
diagnosis [19]. New therapies are critically needed for this
disease.
The anti-apoptotic protein Bcl-2 is overexpressed in the
majority of SCLC cases [20,21]. Suppression of Bcl-2 can
trigger apoptosis in SCLC, and enhance the anti-cancer
efficacy of cytotoxic therapies [22]. ABT-737, a Bcl-2 hom-
ology domain 3 mimetic (BH3), which inhibits the activity
of Bcl-2 and Bcl-XL, has been shown to have potent activ-
ity against many SCLC cell lines [23]. However, the effi-
cacy of ABT-737 is variable across SCLC cell lines, and
this agent has only modest single agent activity against
most primary xenograft models of SCLC [24]. Consistent
with the observed level of activity in primary xenografts,
while clinical trials of ABT-263 (an orally bioavailable de-
rivative of ABT-737 for human use) have shown pharma-
codynamic evidence of on-target activity, the overall
response rate in SCLC patients has been disappointing
[25,26].
We hypothesized that SCLC resistance to ABT-737
may be in part due to cancer cell induction of autoph-
agy. Bcl-2 has been shown to directly bind and inhibit
Beclin-1 (BECN1), a critical mediator of initiation of au-
tophagy [27]. Treatment of HeLa and MCF7 cells with
ABT-737 or gossypol, another purported BH3 mimetic,
has been shown to inhibit the interaction of Beclin-1
and Bcl-2/Bcl-XL and stimulate autophagy [28-30]. We
sought to define whether the treatment of SCLC cell
lines with ABT-737 induces autophagy and whether this
induction is a mechanism of therapeutic resistance. We
also assessed the in vivo efficacy of the combination of
ABT-737 and chloroquine using patient-derived xeno-
graft (PDX) models of SCLC.
Results
To assess whether an inhibitor of autophagy could affect
viability of SCLC cell lines, and could augment the effi-
cacy of the Bcl-2 inhibitor ABT-737, we initially treated
several SCLC cell lines (H82, H209, and H345) withABT-737, chloroquine, or the combination of both agents.
Quantitative assessment of viable cells was performed at
72 hours using a standard MTS assay. In all three cell
lines, the combination of ABT-737 with chloroquine sig-
nificantly decreased cell viability relative to either agent
alone (p < 0.002 for all three, see Figure 1A).
We have previously reported on a series of PDX tumors,
generated by direct transfer of human tumor into im-
munosuppressed mice, which we have used as a preclin-
ical platform for testing novel therapeutic strategies,
including ABT-737 [24,31]. For correlative in vitro ana-
lyses, we have also generated derivative cell lines from two
of these primary xenografts, LX22 and LX33. Cell lines de-
rived from LX22 and LX33 both demonstrated greater loss
of viability, as determined by MTS, in response to the
combination of ABT-737 and chloroquine than to either
agent alone (p < 0.003 for both, see Figure 1B).
These results suggested that inhibition of autophagy
could enhance the efficacy of ABT-737. Alternatively,
chloroquine could be having a cytotoxic effect unrelated
to inhibition of autophagy in these cells. We interrogated
this intersection between apoptotic and autophagic path-
ways using an alternative pharmacologic inhibitor of au-
tophagy, 3-methyladenine (3MA). Treatment with 3MA,
with or without ABT-737, in H209 and H345 cells
resulted in similar results to those obtained with chloro-
quine: clear evidence of enhanced cytotoxic response in
cells treated with the combination relative to either agent
alone (p < 0.0015 for both, see Figure 1C).
We next sought to characterize whether the combina-
torial effects observed in cells treated with ABT-737 and
chloroquine were associated with enhanced apoptosis, as
hypothesized. Caspase-3 activation is a central hallmark of
apoptotic induction through both the extrinsic and intrin-
sic apoptotic pathways. The combination of ABT-737 and
chloroquine resulted in higher levels of caspase-3 activa-
tion relative to either treatment alone in several SCLC
lines (Figure 2A), and in the cell lines derived from pri-
mary patient xenografts (Figure 2B). Chloroquine consist-
ently resulted in less caspase-3 activation than ABT-737,
and in some lines – including both lines derived from pri-
mary patient xenografts – led to almost no caspase-3 acti-
vation as a single agent, yet substantially increased activated
caspase-3 when combined with ABT-737.
Upon activation of autophagy, the LC3-I protein is
phosphatidylethanolamine (PE) conjugated to form LC3-II
and is preferentially translocated to the membranes of
autophagosomes. The appearance of an LC3-II band on
western blots is a generally accepted indicator of autoph-
agy [32]. If apoptotic induction by ABT-737 leads to a
protective autophagic response in cancer cells, then we
might expect to see detectable markers of upregulated
autophagy following ABT-737 exposure, particularly in
























































Figure 1 Combination treatment of ABT-737 with autophagy inhibitors results in decreased proliferation in SCLC cell lines. Cells were
plated in 96-well plates and treated with DMSO, ABT-737, chloroquine (CQ), and the combination of ABT-737 and chloroquine. At 72 hours post-
treatment they were assayed using the MTS cell proliferation assay. Commercially available cell lines are shown in A and cell lines derived from
low passage cultures of primary patient xenografts in B. Doses chosen were based on initial determination of IC50 values and were as follows:
H82 (17 μM ABT-737, 16.5 μM chloroquine), H209 (0.5 μM ABT-737, 20 μM chloroquine), H345 (0.25 μM ABT-737, 94 μM chloroquine), LX22 (6 μM
ABT-737, 40 μM chloroquine), and LX33 (0.8 μM ABT-737, 33 μM chloroquine). C. Similar treatments were performed combining ABT-737 and 3-
methyladenine, another autophagy inhibitor. 3-methyladenine doses were 5 mM for both lines. Error bars: standard deviation (SD); n = 4.
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test this idea, we performed similar single agent and com-
bination drug treatments, and isolated protein to blot for
levels of LC3-II. No LC3-II was detectable in vehicle
control-treated cells, or in cells treated with single agent
ABT-737, but was clearly evident in all cell lines when
treated with chloroquine, and further enhanced by the
combination of chloroquine and ABT-737 (Figure 3A).
Measurement of LC3-II levels showed that for each cell



































Figure 2 Combination of ABT-737 and chloroquine results in increase
the doses listed in Figure 1 for ABT-737 and chloroquine or the combinatio
Luminescence is directly proportional to the amount of caspase-3 activatio
derived from patient xenografts are shown in B. Error bars: SD; n = 4.treatment compared to chloroquine alone (Figure 3B).
These data suggest that ABT-737 may in fact trigger au-
tophagy, as previously suggested [33], but that flux
through the pathway precludes detection of LC3-II unless
an inhibitor of completion of autophagic digestion such
as chloroquine is present. To more conclusively assess
whether ABT-737 induces autophagy, we examined ABT-
737 treated cell lines by transmission electron micros-
copy (TEM) to look for the presence of characteristic

































d induction of apoptosis in SCLC cell lines. Cells were treated at
n for 72 hrs, and then assayed using the Caspase-Glo 3/7 assay.


















































































Figure 3 ABT-737 Treatment induces autophagy in SCLC cell lines. A. Cell lines were treated with doses of ABT-737, CQ, or the combination
at doses indicated in Figure 1 for 72 hrs. Protein lysates were harvested and western blots performed using antibodies for LC3 and β-actin. B.
LC3-II band intensities from the Western blots shown in A of cells treated with CQ vs. ABT & CQ, normalized to Actin as a loading control. C.
H209 and H345 cells were vehicle treated with DMSO (left panels) or treated with ABT-737 (H209, 0.1 μM ABT-737, H345 0.5 μM ABT-737, right
panels) for 72 hrs and harvested for electron microscopy. Block arrows indicate autophagosomes. D. The number of autophagosomes per cell


































































Figure 4 Knockdown of Beclin-1 diminishes the effect of ABT-737. A. shRNA knockdown of BECN1 (KD) or scrambled control (SCR) was
performed in H209 and H345 cells. After puromycin selection, cell lysates were harvested and Western blot analysis was performed using
antibodies specific for Beclin-1 or GAPDH. B. Cells were treated with ABT-737 (0.1 μM), CQ (12.5 μM) or the combination for 72 hrs and then
assayed using the Caspase-Glo 3/7 kit. The y-axis shows fold differences in caspase activation between treatments compared to DMSO treated
samples. Error bars: SD; n = 4.
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small dose-dependent increase in autophagosome forma-
tion in response to ABT-737 in both H209 and H345 cells
(Figure 3C and D). However, statistical significance was
only reached in H209 when comparing 0.5 μM ABT-737
treatment to control (p = 0.025).
While both chloroquine and 3MA appeared to en-
hance the efficacy of ABT-737 against SCLC, these
pharmacologic agents could both be influencing cell pro-
liferation and apoptosis via pathways other than autoph-
agy. In addition, chloroquine may affect completion of
autophagy in cells committed to autophagic induction,
rather than influencing initiation of this pathway. To fur-
ther dissect the potential interactions between the apop-
tosis and autophagy pathways in SCLC, we adopted a
genetic approach, using shRNA knockdown of BECN1
in both H209 and H345 cells (Figure 4A). Beclin-1 is of
particular interest, both an essential autophagy protein
that controls the first steps of autophagic commitment,
and as a known binding partner of the primary targets of
ABT-737, Bcl-2 and Bcl-xL. Surprisingly, and in sharp con-
trast to the results obtained with chloroquine and 3MA,
knockdown of BECN1 decreased caspase-3 activation in
response to ABT-737 and the combination of ABT-737
and chloroquine (Figure 4B).
Similar suppressive effects on apoptotic induction were
seen in H209 and H345. Taken together with data demon-
strating that ABT-737 can activate autophagy (as deter-
mined by LC3-II levels and autophagosome formation),
and that two inhibitors of autophagy (chloroquine and
3MA) can augment ABT-737 efficacy, the entirely unex-
pected results obtained using BECN1 knockdown suggest
that the complex of Bcl-2 and Beclin-1 may have func-
tional significance in the regulation of apoptosis by Bcl-2,
independent of the suppressive effect on autophagy.
It is possible that the inhibitors of autophagy used here
could have biological effects on the regulation of cell
survival independent of the autophagy pathway. Notably,
resistance to ABT-737 in SCLC cell lines has been associ-
ated with increased expression of the anti-apoptotic Bcl-2
family member Mcl-1, which is not effectively inhibited by
ABT-737, and decreased expression of NOXA, a pro-
apoptotic Bcl-2 family member which inhibits Mcl-1 [34].
What is more, both chloroquine and 3-MA have been
shown to decrease Mcl-1 expression in neutrophils [35].
Together, these observations suggest an alternative and po-
tentially complementary mechanism by which the combin-
ation of ABT-737 and chloroquine could effectively inhibit
SCLC growth. To explore whether these mechanisms
might be operant in our cell lines, we performed Western
blotting of Mcl-1, NOXA, and other relevant Bcl-2 family
members in H82, H209, and H345 cells treated with
ABT-737, chloroquine, or combinations of both agents.
As seen in Figure 5, in at least two of these lines (H209and H345), combination therapy was associated with
marked decrease in Mcl-1. H209 did not express detectable
NOXA under any conditions, but in the other two lines,
combination therapy was also associated with NOXA
upregulation. These data suggest that at least part of the
combinatorial effect of ABT-737 and chloroquine may be
mediated by alteration in the relative balance of pro- and
anti-apoptotic Bcl-2 family members, promoting cell death.
Finally, given the observed enhanced cytotoxicity seen
in vitro through combination of ABT-737 and chloroquine,
we sought to explore whether this combination could im-
prove tumor control in vivo. Cohorts of established tumor
xenografts of the cell line H209, as well as three SCLC PDX
models, LX22, LX33, and LX44, were treated with daily in-
traperitoneal injection of chloroquine, ABT-737, combin-
ation, or vehicle-treated controls, and tumor volume was
monitored over time. The combination was superior to sin-
gle agent treatment in the H209 xenografts (p = 0.005 for
comparison with ABT-737 alone), but showed no evidence
of superiority over ABT-737 alone in the treatment of the
primary xenograft models (p > 0.5 for comparison with
ABT-737 alone in the primary xenografts) (Figure 6). The
interaction p-value remains significant for H209 with a
Bonferroni correction for multiple testing (p = 0.02).
Discussion
In this study we sought to assess whether the efficacy of
the targeted Bcl-2 inhibitor, ABT-737, against SCLC could
be improved by concurrent inhibition of autophagy with
the clinically available agent chloroquine. In vitro analyses
of the combination of ABT-737 and chloroquine in several
SCLC cell lines did show a decrease in viability and a con-
comitant increase in caspase-3 activation. In addition, we
found evidence that ABT-737 induced autophagy in sev-
eral cell lines by the conversion of LC3-I to LC3-II seen
on western blots and increased autophagosome formation
as documented by TEM.
However, a targeted genetic approach to blocking entry
into autophagy based on shRNA knockdown of BECN1
yielded the opposite result: a consistent decrease in apop-
totic response to ABT-737, with or without chloroquine.
There are several possible explanations for these seem-
ingly contradictory results. First, the effects seen with
chloroquine may not have been specific to the autophagy
pathway. Indeed, we were able to demonstrate that the
combination of ABT-737 and chloroquine can lead to
marked inhibition of Mcl-1 and upregulation of NOXA,
both of which would serve to facilitate apoptotic induc-
tion, independent of an effect on autophagy. It is known
that chloroquine can also act on several other pathways
including those involved in immune modulation and
DNA damage [17].
Second, while chloroquine inhibits the late stages of au-
tophagy, i.e. the fusion of autophagosomes with lysosomes
Figure 5 ABT-737 and chloroquine combination therapy alters the expression levels of apoptotic regulatory factors in SCLC. The cell
lines H82, H209 and H345 were treated with DMSO (control), ABT-737, CQ, and combinations of the two drugs for 72 hours before protein lysates
were isolated. Doses of ABT-737 and CQ that were below or approximating the cell line specific IC50 values for each agent were chosen. Beta-
actin is shown as an internal loading control and cleaved-PARP is shown for relative induction of apoptosis. NOXA was undetectable in H209 and
Bcl-2 was barely detectable in H82.
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quired for an initial commitment toward autophagy. It is
possible that successful initiation of autophagy without
the ability to complete the process leads to intracellular
accumulation of toxic materials, leading to enhanced
apoptotic cell death, while blockade of entry into this
pathway does not. Some reports do suggest that specificFigure 6 Combination of ABT-737 and chloroquine does not result in
mice (4–7 per treatment arm) were treated daily with ABT-737 (100 mg/kg
control for 18–21 days. Tumor volumes were measured every three days. G
are shown.stage of autophagy inhibition can result in different thera-
peutic outcomes [5,36]. Our data with 3MA would argue
against this explanation to some extent: 3MA inhibits ini-
tiation of autophagy at a stage closely related to that of
Beclin-1, but unlike Beclin-1 suppression, augmented the
apoptotic response to ABT-737 in multiple lines. 3MA is a
class I and class III PI3K inhibitor [14], and could, likeincreased efficacy in xenografts models. Tumor bearing Nu/Nu
, IP),CQ (60 mg/kg, IP), combination, or an equal amount of vehicle
roup means and standard error of the mean for each measurement
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hanced programmed cell death.
Third, and perhaps most intriguingly, Beclin-1 and
Bcl-2 are known to directly interact, and shRNA suppres-
sion of BECN1 may affect Bcl-2 function or localization
independent of any effect on induction of autophagy.
While previous data suggest that Beclin-1 does not affect
the anti-apoptotic activity or localization of Bcl-2, this
finding may be context and cell type-specific; these studies
were performed in HeLa cervical carcinoma cells and
mouse embryonic fibroblasts [37]. One possible model to
explain our results would be if Beclin-1 sequesters some
fraction of the cellular Bcl-2 away from the mitochondrial
membrane, where Bcl-2 primarily acts to suppress outer
mitochondrial membrane disruption. Targeted loss of
Beclin-1 could lead to a preferential localization of Bcl-2
to mitochondria, decreasing ABT-737 efficacy by func-
tional upregulation of the target. The novel observations
in this study suggest several testable hypotheses to be
addressed in future studies, which may provide additional
insights into the interface between regulators of apoptosis
and autophagy in SCLC.
Conclusions
Several ongoing clinical trials seek to evaluate the efficacy
of autophagy inhibitors in combination with cytotoxic
therapies in cancer types including SCLC. The data
presented here have important implications for studies in
SCLC. Different strategies for modulating autophagy can
have markedly discordant effects on the efficacy of cyto-
toxic therapies. It will be important to study the modula-
tion of autophagy closely in relevant preclinical models to
anticipate possible combinatorial effects.
In work presented here, we analyzed for the first time
the effect of combining ABT-737 and chloroquine in
SCLC models, including assessment of activity against
PDX tumors, models that may better reflect the biology of
disease than do cell line-based xenografts [31,38]. Our
in vivo xenograft data, particularly in the three primary
xenograft models, suggest that despite some intriguing
molecular interactions, the combination of ABT-737 and
chloroquine is unlikely to have significant anti-cancer ac-
tivity against SCLC, relative to ABT-737 alone.
Methods
Cell lines
All cell lines were obtained from American Type Culture
Collection and grown in the recommended media. Pri-
mary xenograft cell lines (LX) were derived from patient
tumors as previously described [31].
MTS cell proliferation assays
Cells were plated in quadruplicate and treated with
ABT-737 and chloroquine for 72 hours at indicated doses.MTS cell proliferation assays were performed following
manufacturer instructions using the CellTiter 96 AQueous
One Solution Cell Proliferation Assay (Promega).
Caspase-Glo 3/7 assay. Assay was performed following
manufacturer instructions (Promega). Briefly, 20,000 vi-
able cells from each sample were transferred to 96-well
white-walled plates in 75–100 μl total volume of culture
medium. An equal volume of Caspase-Glo 3/7 Reagent
was added to each well. Assays were performed in quadru-
plicate. Plates were covered and incubated at room
temperature for 1–2 hours before measuring lumines-
cence on a plate reading luminometer. The luminescence
reading is directly proportional to caspase-3 activity.
Western blotting
Protein was isolated from cell pellets using radioim-
munoprecipitation assay buffer (Sigma) and run on 10 or
12% Bis-Tris gels with MOPS or MES running buffer
(Invitrogen). Membranes were probed with antibodies for
LC3, Beclin-1, GAPDH, β-Actin (Santa Cruz), Mcl-1 (BD
Pharmigen; #559027), Bax (Santa Cruz; #sc-6236), Bcl-XL
(Cell Signaling; #2764), Bcl-2 (Santa Cruz; #sc-492), NOXA
(Imgenex; #IMG-349A), PUMA (Cell Signaling; #4976),
and cleaved PARP (Cell Signaling; #5625) following manu-
facturer instructions.
Electron microscopy
Samples were fixed in 2.5% glutaraldehyde, 3 mM CaCl2,
1% sucrose, in 0.1 M sodium cacodylate buffer, pH 7.2 for
one hour at room temperature. After buffer rinse, samples
were postfixed in 1% osmium tetroxide in buffer (1 hr) on
ice in the dark. Following a DH2O rinse, plates were
stained with 2% aqueous uranyl acetate (0.22 μm filtered,
1 hr, dark), dehydrated in a graded series of ethanol and
embedded in Eponate 12 (Ted Pella) resin. Samples were
polymerized at 60°C overnight. Thin sections, 60 to
90 nm, were cut with a diamond knife on the Reichert-
Jung Ultracut E ultramicrotome and picked up with naked
200 mesh copper grids. Grids were stained with 2% uranyl
acetate in 50% methanol and observed with a Philips CM
120 at 80 kV. Images were captured with an Advanced
Microscopy Techniques transmission electron microscopy
(1 K × 1 K) camera.
Lentiviral shRNA and cDNA overexpression experiments
Lentiviral particles were generated using a three-plasmid
system and infected as per the RNAi Consortium Library
Production and Performance Protocols, Broad Institute
[39]. shRNA constructs were obtained from the Broad
RNAi Consortium and screened for knockdown. The
BECN1 shRNA clone ID TRCN0000033550 was used
these experiments. pLKO.1-shRNA scramble vector was
obtained from Dr. David M. Sabatini through Addgene
(Addgene plasmid 1864) as previously described [40].
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Patient-derived xenograft tumor models LX22, LX33, and
LX44 were generated as previously described [24,31]. NCI-
H209 cells (1 × 107), or SCLC patient derived tumor cells
LX22 (1.5 × 106), LX33 (1.6 × 106), and LX44 (3.5 × 106),
were suspended in a 1:1 ratio of PBS and matrigel (BD
Biosciences). Cell suspensions were injected subcutane-
ously on right hind flanks of female nu/nu 6 – 8 week old
mice (Charles River). Drug treatments began when tumor
sizes reached 200 mm3. Mice were treated daily with
100 mg/kg ABT-737 (IP), 60 mg/kg chloroquine (IP),
combination or vehicle treated for 21 days. Tumors were
measured with a manual caliper every 3 days and volumes
were calculated using the formula: tumor weight (mg) =
[length (mm) x width2 (mm2)]/2. In order to test whether
treatment inhibited tumor growth, we used a mixed ef-
fects linear model comparing tumor growth between
ABT-737 and ABT-737 and CQ treatment groups, model-
ing the log of tumor size over time and including an inter-
action term. All in vivo experiments were conducted with
protocol approval by the Johns Hopkins Animal Care and
Use Committee.
Statistical analyses
The student’s t-test was used to compare combination
treatment effects vs. single agent treatment effects in cell
lines. For in vivo analyses of whether treatment inhibited
tumor growth, we used a mixed effects linear model
comparing tumor growth between treatment groups,
modeling the log of tumor size over time and including
an interaction term. A p value <0.05 was considered
significant.
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